Russell Investments Group Ltd. boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 36.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 953,167 shares of the company’s stock after acquiring an additional 252,553 shares during the quarter. Russell Investments Group Ltd. owned about 0.20% of Zoetis worth $60,763,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Ironwood Investment Management LLC increased its stake in Zoetis by 0.7% during the second quarter. Ironwood Investment Management LLC now owns 6,870 shares of the company’s stock worth $429,000 after acquiring an additional 48 shares during the last quarter. Benjamin F. Edwards & Company Inc. increased its stake in Zoetis by 1.3% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 4,201 shares of the company’s stock worth $262,000 after acquiring an additional 55 shares during the last quarter. Wilbanks Smith & Thomas Asset Management LLC increased its stake in Zoetis by 1.8% during the second quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 5,682 shares of the company’s stock worth $354,000 after acquiring an additional 98 shares during the last quarter. First Manhattan Co. increased its stake in Zoetis by 1.1% during the second quarter. First Manhattan Co. now owns 9,099 shares of the company’s stock worth $567,000 after acquiring an additional 99 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC increased its stake in Zoetis by 1.3% during the second quarter. Gilder Gagnon Howe & Co. LLC now owns 7,795 shares of the company’s stock worth $486,000 after acquiring an additional 100 shares during the last quarter. 92.44% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/11/18/zoetis-inc-zts-holdings-raised-by-russell-investments-group-ltd.html.

Zoetis Inc. (NYSE ZTS) traded up $0.38 during trading hours on Friday, reaching $70.79. The company had a trading volume of 2,337,803 shares, compared to its average volume of 2,806,257. The stock has a market capitalization of $34,310.00, a price-to-earnings ratio of 32.06, a PEG ratio of 2.04 and a beta of 1.02. Zoetis Inc. has a 52-week low of $48.55 and a 52-week high of $71.12. The company has a debt-to-equity ratio of 2.45, a quick ratio of 1.95 and a current ratio of 2.80.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.63 by $0.02. The firm had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.32 billion. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. Zoetis’s revenue was up 8.5% compared to the same quarter last year. During the same period last year, the business posted $0.52 earnings per share. equities analysts anticipate that Zoetis Inc. will post 2.37 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Thursday, November 9th will be issued a $0.105 dividend. The ex-dividend date of this dividend is Wednesday, November 8th. This represents a $0.42 dividend on an annualized basis and a yield of 0.59%. Zoetis’s dividend payout ratio (DPR) is presently 22.11%.

ZTS has been the subject of a number of research reports. BMO Capital Markets reaffirmed a “hold” rating and issued a $65.00 price objective on shares of Zoetis in a research note on Thursday, November 2nd. Cantor Fitzgerald set a $75.00 price objective on Zoetis and gave the company a “buy” rating in a research note on Monday, August 14th. Cowen and Company set a $80.00 price objective on Zoetis and gave the company a “buy” rating in a research note on Friday. Stifel Nicolaus reaffirmed a “buy” rating and issued a $65.00 price objective on shares of Zoetis in a research note on Friday, September 1st. Finally, BidaskClub cut Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, September 20th. One analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $67.65.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.